CN109859851A - A kind of therapeutic scheme recommended method and device - Google Patents
A kind of therapeutic scheme recommended method and device Download PDFInfo
- Publication number
- CN109859851A CN109859851A CN201811606759.9A CN201811606759A CN109859851A CN 109859851 A CN109859851 A CN 109859851A CN 201811606759 A CN201811606759 A CN 201811606759A CN 109859851 A CN109859851 A CN 109859851A
- Authority
- CN
- China
- Prior art keywords
- therapeutic scheme
- candidate therapeutic
- scheme
- drug
- data
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 322
- 238000000034 method Methods 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 175
- 229940079593 drug Drugs 0.000 claims abstract description 152
- 208000024891 symptom Diseases 0.000 claims abstract description 33
- 238000012216 screening Methods 0.000 claims description 38
- 238000003860 storage Methods 0.000 claims description 21
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 19
- 201000005311 drug allergy Diseases 0.000 claims description 19
- 230000015654 memory Effects 0.000 claims description 17
- 230000007717 exclusion Effects 0.000 claims description 2
- 206010067484 Adverse reaction Diseases 0.000 description 8
- 230000006838 adverse reaction Effects 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000004590 computer program Methods 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 2
- 229960001625 furazolidone Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- -1 Compound Diphenoxylate Chemical class 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Landscapes
- Medical Treatment And Welfare Office Work (AREA)
Abstract
The embodiment of the invention provides a kind of therapeutic scheme recommended method and devices, and the present invention relates to big data fields, this method comprises: obtaining the illness information of target patient, illness information includes at least the symptom of target patient；Therapeutic scheme is searched from target database according to the illness information of target patient, obtain multiple candidate therapeutic schemes, the illness information and therapeutic scheme of multiple patients are stored in target database, similarity between the symptom of the associated patient of candidate therapeutic scheme and the symptom of target patient meets preset condition, and candidate therapeutic scheme includes at least nomenclature of drug and drug dosage；Obtain the first clinical application data；Multiple candidate therapeutic schemes are screened according to the first clinical application data, obtain at least one goal treatment scheme；Export goal treatment scheme.Therefore, technical solution provided in an embodiment of the present invention be able to solve part doctor in the prior art lead to not from want of experience for patient formulate reasonable therapeutic scheme the problem of.
Description
[technical field]
The present invention relates to big data field more particularly to a kind of therapeutic scheme recommended method and devices.
[background technique]
Doctor is that patient carries out diagnosis and formulate therapeutic scheme to be the Couple herbs by doctor itself at present, part doctor by
Lead to not formulate reasonable therapeutic scheme for patient in lacking experience.
[summary of the invention]
In view of this, the embodiment of the invention provides a kind of therapeutic scheme recommended method and devices, to solve existing skill
Part doctor leads to not the problem of formulating reasonable therapeutic scheme for patient from want of experience in art.
On the one hand, the embodiment of the invention provides a kind of therapeutic scheme recommended methods, which comprises obtains target and suffers from
The illness information of person, the illness information include at least the symptom of the target patient；Believed according to the illness of the target patient
Breath searches therapeutic scheme from target database, obtains multiple candidate therapeutic schemes, stores in the target database multiple
The illness information and therapeutic scheme of patient, the symptom of the associated patient of candidate therapeutic scheme and the symptom of the target patient
Between similarity meet preset condition, the candidate therapeutic scheme includes at least nomenclature of drug and drug dosage；Obtain first
Clinical application data, the first clinical application data include at least the clinical application data of target medicine, the target medicine
The drug for including for the candidate therapeutic scheme；According to the first clinical application data to the multiple candidate therapeutic scheme into
Row screening, obtains at least one goal treatment scheme；Export the goal treatment scheme.
Further, the first clinical application data include incompatible number evidence and medication taboo data, the basis
The first clinical application data screen the multiple candidate therapeutic scheme, comprising: according to the incompatibility data
The multiple candidate therapeutic scheme is screened；And/or data are avoided to the multiple candidate therapeutic side according to the medication
Case is screened.
It is further, described that the multiple candidate therapeutic scheme is screened according to the incompatibility data, comprising:
Judge whether the first candidate therapeutic scheme includes two or more drug, and the first candidate therapeutic scheme is described more
Any one candidate therapeutic scheme in a candidate therapeutic scheme；If the first candidate therapeutic scheme includes two kinds or two kinds
Above drug then obtains the incompatibility data for all drugs that the first candidate therapeutic scheme includes；According to described
The incompatible numbers of all drugs that one candidate therapeutic scheme includes it is judged that the first candidate therapeutic scheme with the presence or absence of matching
5 taboo situations；If there are incompatibility situations for the first candidate therapeutic scheme, the first candidate therapeutic side is excluded
Case.
It is further, described that the multiple candidate therapeutic scheme is screened according to medication taboo data, comprising:
Data are avoided in the medication for all drugs for including from the first clinical application data acquisition the first candidate therapeutic scheme, described
First candidate therapeutic scheme is any one candidate therapeutic scheme in the multiple candidate therapeutic scheme；Prohibited according to the medication
Avoid the applicable group for all drugs that data determine that the first candidate therapeutic scheme includes；Judge whether the target patient belongs to
In the applicable group for each drug that the first candidate therapeutic scheme includes；If the target patient is not belonging to described
The applicable group for any one or more drug that one candidate therapeutic scheme includes then excludes the first candidate therapeutic scheme.
Further, the multiple candidate therapeutic scheme is screened according to the first clinical application data described
Before, the method also includes: obtain the drug allergy history of the target patient；According to the drug allergy of the target patient
History screens the multiple candidate therapeutic scheme.
On the one hand, the embodiment of the invention provides a kind of therapeutic scheme recommendation apparatus, described device includes: the first acquisition list
Member, for obtaining the illness information of target patient, the illness information includes at least the symptom of the target patient；It searches single
Member obtains multiple candidate therapeutics for searching therapeutic scheme from target database according to the illness information of the target patient
Scheme stores the illness information and therapeutic scheme of multiple patients, the candidate therapeutic scheme association in the target database
The symptom of patient and the symptom of the target patient between similarity meet preset condition, the candidate therapeutic scheme is at least
Including nomenclature of drug and drug dosage；Second acquisition unit, for obtaining the first clinical application data, first clinical application
Data include at least the clinical application data of target medicine, and the target medicine is the drug that the candidate therapeutic scheme includes；
First screening unit is obtained for being screened according to the first clinical application data to the multiple candidate therapeutic scheme
At least one goal treatment scheme；Output unit, for exporting the goal treatment scheme.
Further, the first clinical application data include incompatible number evidence and medication taboo data, described first
Screening unit includes: the first screening subelement, for according to the incompatibility data to the multiple candidate therapeutic scheme into
Row screening；And/or second screening subelement, for according to the medication avoid data to the multiple candidate therapeutic scheme into
Row screening.
Further, the first screening subelement includes: first judgment module, for judging the first candidate therapeutic scheme
It whether include two or more drug, the first candidate therapeutic scheme is appointing in the multiple candidate therapeutic scheme
It anticipates a candidate therapeutic scheme；First obtain module, if for the first candidate therapeutic scheme include two kinds or two kinds with
On drug, then obtain the incompatibility data for all drugs that the first candidate therapeutic scheme includes；Second judgment module,
The incompatible number of all drugs for including according to the first candidate therapeutic scheme is it is judged that first candidate therapeutic
Scheme whether there is incompatibility situation；First excludes module, if there are compatibility taboos for the first candidate therapeutic scheme
Avoid situation, then excludes the first candidate therapeutic scheme.
Further, the second screening subelement includes: the second acquisition module, is used for from the first clinical application number
Data are avoided according to the medication for all drugs for including in the first candidate therapeutic scheme that obtains, the first candidate therapeutic scheme is institute
State any one candidate therapeutic scheme in multiple candidate therapeutic schemes；Determining module, for avoiding data according to the medication
Determine the applicable group for all drugs that the first candidate therapeutic scheme includes；Third judgment module, for judging the mesh
Whether mark patient belongs to the applicable group for each drug that the first candidate therapeutic scheme includes；Second excludes module, uses
If being not belonging to the applicable group for any one or more drug that the first candidate therapeutic scheme includes in the target patient
Body then excludes the first candidate therapeutic scheme.
Further, described device further include: third acquiring unit, in first screening unit according to described the
Before one clinical application data screen the multiple candidate therapeutic scheme, the drug allergy for obtaining the target patient is gone through
History；Second screening unit, for being carried out according to the drug allergy history of the target patient to the multiple candidate therapeutic scheme
Screening.
On the one hand, the embodiment of the invention provides a kind of storage medium, the storage medium includes the program of storage,
In, equipment where controlling the storage medium in described program operation executes above-mentioned therapeutic scheme recommended method.
On the one hand, the embodiment of the invention provides a kind of computer equipment, including memory and processor, the memories
For storing the information including program instruction, the processor is used to control the execution of program instruction, and described program instruction is located
The step of reason device loads and realizes above-mentioned therapeutic scheme recommended method when executing.
In embodiments of the present invention, according to the illness information of target patient, existing therapeutic scheme is looked into from database
It looks for, searches the associated therapeutic scheme of patient similar with the symptom of target patient, the therapeutic scheme found is controlled as candidate
Treatment scheme screens multiple candidate therapeutic schemes according to clinical application data, obtains at least one goal treatment scheme, defeated
Goal treatment scheme out, even the insufficient doctor of experience also can make full use of existing therapeutic scheme and clinical application data
Reasonable therapeutic scheme is made for patient, part doctor in the prior art is solved and leads to not from want of experience for patient
The problem of formulating reasonable therapeutic scheme.
[Detailed description of the invention]
In order to illustrate the technical solution of the embodiments of the present invention more clearly, below will be to needed in the embodiment attached
Figure is briefly described, it should be apparent that, drawings in the following description are only some embodiments of the invention, for this field
For those of ordinary skill, without any creative labor, it can also be obtained according to these attached drawings other attached
Figure.
Fig. 1 is a kind of flow chart of optional therapeutic scheme recommended method provided in an embodiment of the present invention；
Fig. 2 is a kind of schematic diagram of optional therapeutic scheme recommendation apparatus provided in an embodiment of the present invention；
Fig. 3 is a kind of schematic diagram of optional computer equipment provided in an embodiment of the present invention.
[specific embodiment]
For a better understanding of the technical solution of the present invention, being retouched in detail to the embodiment of the present invention with reference to the accompanying drawing
It states.
It will be appreciated that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Base
Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts it is all its
Its embodiment, shall fall within the protection scope of the present invention.
The term used in embodiments of the present invention is only to be not intended to be limiting merely for for the purpose of describing particular embodiments
The present invention.In the embodiment of the present invention and the "an" of singular used in the attached claims, " described " and "the"
It is also intended to including most forms, unless the context clearly indicates other meaning.
It should be appreciated that term "and/or" used herein is only a kind of incidence relation for describing affiliated partner, indicate
There may be three kinds of relationships, for example, first and/or second, can indicate: individualism first exists simultaneously first and second, individualism second
These three situations.In addition, character "/" herein, typicallys represent the relationship that forward-backward correlation object is a kind of "or".
Fig. 1 is a kind of flow chart of optional therapeutic scheme recommended method provided in an embodiment of the present invention, as shown in Figure 1,
This method comprises:
Step S102, obtains the illness information of target patient, and illness information includes at least the symptom of target patient.
Step S104 searches therapeutic scheme according to the illness information of target patient from target database, obtains multiple times
Therapeutic scheme is selected, the illness information and therapeutic scheme of multiple patients are stored in target database, candidate therapeutic scheme is associated
Similarity between the symptom of patient and the symptom of target patient meets preset condition, and candidate therapeutic scheme includes at least drug name
Title and drug dosage.
Step S106, obtains the first clinical application data, and the first clinical application data include at least the clinic of target medicine
Administration data, target medicine are the drug that candidate therapeutic scheme includes.
Step S108 screens multiple candidate therapeutic schemes according to the first clinical application data, obtains at least one
Goal treatment scheme.
Step S110 exports goal treatment scheme.
In embodiments of the present invention, according to the illness information of target patient, existing therapeutic scheme is looked into from database
It looks for, searches the associated therapeutic scheme of patient similar with the symptom of target patient, the therapeutic scheme found is controlled as candidate
Treatment scheme screens multiple candidate therapeutic schemes according to clinical application data, obtains at least one goal treatment scheme, defeated
Goal treatment scheme out, even the insufficient doctor of experience also can make full use of existing therapeutic scheme and clinical application data
Reasonable therapeutic scheme is made for patient, part doctor in the prior art is solved and leads to not from want of experience for patient
The problem of formulating reasonable therapeutic scheme.
Optionally, the first clinical application data include incompatible number evidence, according to the first clinical application data to multiple times
It selects therapeutic scheme to be screened, specifically may is that and multiple candidate therapeutic schemes are screened according to incompatibility data.
Multiple candidate therapeutic schemes are screened according to incompatibility data, specifically may is that and judge that the first candidate controls
Whether treatment scheme includes two or more drug, and the first candidate therapeutic scheme is any in multiple candidate therapeutic schemes
One candidate therapeutic scheme；If the first candidate therapeutic scheme includes two or more drug, it is candidate to obtain first
The incompatibility data for all drugs that therapeutic scheme includes；According to the compatibility for all drugs that the first candidate therapeutic scheme includes
Taboo data judge the first candidate therapeutic scheme with the presence or absence of incompatibility situation；If there are compatibilities for the first candidate therapeutic scheme
Situation is avoided, then excludes the first candidate therapeutic scheme.
Compatibility of drugs refers to that two or more drug is blended in one during medicament manufacture or clinical application
It rises.When a kind of curative effect of medication of application is bad, it is necessary to other drugs be selected to carry out reasonable compatibility.
Compatibility of drugs can appropriately improve powder performance, heighten the effect of a treatment, such as select additives appropriate so that medicament stablize,
Oral ferrous salt Shi Jiayong vitamin C can increase absorption etc..
But not all drug compatibility is all reasonably, some drug compatibilities weaken the therapeutic effect of drug, lead
Cause treatment failure；Some drug compatibilities enhance side effect or toxicity, cause serious adverse reaction；Also some drug compatibilities make to control
Overaction enhancing is treated, the ability that body is resistant to is had exceeded, adverse reaction can also be caused, or even endanger patient etc..
In compatibility, claim incompatibility if being unfavorable for the variation of quality or treatment.Incompatibility be divided into it is physical,
Chemically with pharmacological three classes.Physical behavior variation, such as some drugs have occurred in physical incompatibility when referring to compatibility of drugs
Eutectic mixture can be formed when lapping-in, disfeature character, causes using difficulty.Chemical incompatibility refers to compatibility process
In have occurred chemical change, precipitating, redox, metachromasia occurs, makes drug decomposition failure.Pharmacological incompatibility refers to
The pharmacodynamic change occurred after compatibility increases toxicity etc..
For example, the compatibility of drug A and drug B will increase toxicity, having a kind of candidate therapeutic scheme includes drug A and drug B
Compatibility, then exclude the candidate therapeutic scheme.
Part candidate therapeutic scheme may have some problems in itself, for example, not accounting for compatibility of drugs may lead
The incompatibility of cause, using incompatibility as one of the condition of screening candidate therapeutic scheme, filter out may result in this programme
The candidate therapeutic scheme of incompatibility improves safety, science and the validity of the therapeutic scheme filtered out.
Optionally, the first clinical application data include medication taboo data, according to the first clinical application data to multiple times
It selects therapeutic scheme to be screened, specifically may is that avoiding data according to medication screens multiple candidate therapeutic schemes.
Data are avoided according to medication to screen multiple candidate therapeutic schemes, specifically may is that from the first clinical application
Data are avoided in the medication for all drugs for including in data acquisition the first candidate therapeutic scheme, and the first candidate therapeutic scheme is multiple
Any one candidate therapeutic scheme in candidate therapeutic scheme；Data, which are avoided, according to medication determines that the first candidate therapeutic scheme includes
All drugs applicable group；Judge whether target patient belongs to the suitable of each drug that the first candidate therapeutic scheme includes
Use group；If target patient is not belonging to the applicable group for any one or more drug that the first candidate therapeutic scheme includes,
Then exclude the first candidate therapeutic scheme.
Medication taboo includes Drugs during pregnancy taboo, children taboo etc..
Drugs during pregnancy taboo citing:
Agents disabling is in gestation or by the patient of gestation: methotrexate (MTX) (can cause fetus harelip, cleft palate, anencephalus, brain
Ponding, meninx bulging etc.), Ribavirin, Misoprostol, Simvastatin, fluorouracil, warfarin, Goserelin, take fluorine rice
Spy, dilantin sodium, sodium vedproate, carbamazepine, estazolam etc..
Children taboo citing:
Aspirin: newborn's disabling
Furantoin, furazolidone (furazolidone): newborn's disabling (can cause hemolytic anemia of newborn, multiple mind
Through inflammation)
Brufen: it disables within 6 months or less
Miconazole: 1 years old or less children's disabling
Cyclosporine: 1 years old or less baby's disabling
Albendazole (zental): 2 years old or less children's disabling
Compound Diphenoxylate: 2 years old or less children's disabling
Omeprazole: 3 years old or less children's disabling
An Su: 4 years old or less children's disablings
Hydroxychloroquine: 6 years old or less children's disabling
Ranitidine: 8 years old or less children's disabling
For example, it is assumed that the symptom according to target patient searches therapeutic scheme from target database, 8 candidate therapeutics are obtained
Scheme, respectively candidate therapeutic scheme 1, candidate therapeutic scheme 2, candidate therapeutic scheme 3, candidate therapeutic scheme 4, candidate therapeutic side
Case 5, candidate therapeutic scheme 6, candidate therapeutic scheme 7, candidate therapeutic scheme 8.Assuming that candidate therapeutic scheme 1 is to candidate therapeutic scheme
6 include this drug of peace element.Assuming that the age of target patient is 3 years old, then avoided according to children, peace element for 4 years old with
Lower children's disabling, therefore, candidate therapeutic scheme 1 to candidate therapeutic scheme 6 is not suitable therapeutic scheme, excludes candidate therapeutic
Scheme 1 is to candidate therapeutic scheme 6.
Optionally, the first clinical application data include incompatible number evidence and medication taboo data, according to the first clinical use
Medicine data screen multiple candidate therapeutic schemes, specifically may is that according to incompatibility data to multiple candidate therapeutic sides
Case is screened；And it avoids data according to medication to screen multiple candidate therapeutic schemes.
Before being screened according to the first clinical application data to multiple candidate therapeutic schemes, it can also be suffered from according to target
The drug allergy history of person carries out preliminary screening to multiple candidate therapeutic schemes, specifically may is that the drug for obtaining target patient
Allergy history；Multiple candidate therapeutic schemes are screened according to the drug allergy history of target patient.
The drug mistake whether target patient includes to candidate therapeutic scheme is judged according to the drug allergy history of target patient
It is quick；If any one or more drug allergy that target patient includes to candidate therapeutic scheme, excludes the candidate therapeutic side
Case.
Drug allergy is also referred to as drug allergy, is drug-induced allergic reaction, is one in adverse drug reaction
Kind specific type is related to the specific allergy constitution of people.Drug allergy should generally have more typical allergic conditions or body
Sign.Belonging to I type allergy sufferers often has fash, skin itch, sneeze, runny nose, asthma attack or even anasarca, blood pressure decline, shock
Deng.Belonging to II type person often has anaemia, bleeding, purpura etc..Belonging to III type person has fever, enlargement of lymph nodes, painful swelling of joints, kidney damage
Evil etc..Belonging to IV often has eczema, the bleb of fixation, the clear cutaneous pigmentation of circumference etc..
If some candidate therapeutic scheme includes drug A, and the bright target patient of drug allergy history lists of target patient
To drug A allergy, then the candidate therapeutic scheme is excluded.
It can also be according to the adverse reaction screening candidate therapeutic scheme for having treated patient.Specifically, if some candidate controls
Treatment scheme causes the adverse reaction of patient than more serious, then excludes the candidate therapeutic scheme.If some candidate therapeutic scheme is led
The adverse reaction of cause patient is smaller or patient has no adverse reaction, then retains the candidate therapeutic scheme.
For example, it is assumed that there is a candidate therapeutic scheme to be once used for patient's first, the nervous system of patient's first is caused to have serious damage
Evil, then exclude the candidate therapeutic scheme.
Adverse reaction classification of severity:
1) slight: to refer to slight reaction or disease, symptom does not develop, general without treatment.
2) moderate: referring to that adverse reaction symptom is obvious, and vitals or system function have moderate damage.
3) severe: referring to that vitals or system function have serious damage, leads to disabled or shortening or threat to life.
By screening therapeutic scheme according to the adverse reaction of patient, the safety of therapeutic scheme ensure that.
The embodiment of the invention provides a kind of drug recommender system, which has got through the data barrier between hospital and medicine enterprise
Hinder, medicine enterprise provides clinical application data for hospital, and hospital provides patient treatment data for doctor, and doctor only needs typing patient's
Corresponding illness information, system can intelligently compare controlling for patient data and Different hospital same type patient by big data analysis
Treatment scheme and the clinical application data of medicine enterprise, find out the therapeutic scheme for being most suitable for the patient, finally provide for doctor for this
Optimal therapeutic scheme for patient.
The system gets through the obstacle data between each hospital and medicine enterprise, provides more data references for doctor, for doctor
It is raw that more therapeutic regimens selections are provided, provide better therapeutic scheme for patient, take full advantage of existing medical resource with
Data resource improves the working efficiency of doctor.
The embodiment of the invention provides a kind of therapeutic scheme recommendation apparatus, which recommends for executing above-mentioned therapeutic scheme
Method, as shown in Fig. 2, the device includes: first acquisition unit 10, searching unit 20, the screening list of second acquisition unit 30, first
First 40, output unit 50.
First acquisition unit 10, for obtaining the illness information of target patient, illness information includes at least target patient
Symptom.
Searching unit 20 is obtained for searching therapeutic scheme from target database according to the illness information of target patient
Multiple candidate therapeutic schemes store the illness information and therapeutic scheme of multiple patients, candidate therapeutic scheme in target database
Similarity between the symptom of associated patient and the symptom of target patient meets preset condition, and candidate therapeutic scheme includes at least
Nomenclature of drug and drug dosage.
Second acquisition unit 30, for obtaining the first clinical application data, the first clinical application data include at least target
The clinical application data of drug, target medicine are the drug that candidate therapeutic scheme includes.
First screening unit 40 is obtained for being screened according to the first clinical application data to multiple candidate therapeutic schemes
To at least one goal treatment scheme.
Output unit 50, for exporting goal treatment scheme.
In embodiments of the present invention, according to the illness information of target patient, existing therapeutic scheme is looked into from database
It looks for, searches the associated therapeutic scheme of patient similar with the symptom of target patient, the therapeutic scheme found is controlled as candidate
Treatment scheme screens multiple candidate therapeutic schemes according to clinical application data, obtains at least one goal treatment scheme, defeated
Goal treatment scheme out, even the insufficient doctor of experience also can make full use of existing therapeutic scheme and clinical application data
Reasonable therapeutic scheme is made for patient, part doctor in the prior art is solved and leads to not from want of experience for patient
The problem of formulating reasonable therapeutic scheme.
Optionally, the first clinical application data include incompatible number evidence, and the first screening unit 40 includes: the first screening
Unit.First screening subelement, for being screened according to incompatibility data to multiple candidate therapeutic schemes.
Optionally, the first clinical application data include medication taboo data, and the first screening unit 40 includes: the second screening
Unit.Second screening subelement, screens multiple candidate therapeutic schemes for avoiding data according to medication.
Optionally, the first clinical application data include incompatible number evidence and medication taboo data, the first screening unit 40
It include: the first screening subelement and the second screening subelement.First screening subelement, is used for according to incompatibility data to multiple
Candidate therapeutic scheme is screened.Second screening subelement, for according to medication avoid data to multiple candidate therapeutic schemes into
Row screening.
Optionally, the first screening subelement includes: first judgment module, the first acquisition module, the second judgment module, first
Exclude module.First judgment module, for judging whether the first candidate therapeutic scheme includes two or more drug,
One candidate therapeutic scheme is any one candidate therapeutic scheme in multiple candidate therapeutic schemes.First obtains module, for such as
Fruit the first candidate therapeutic scheme includes two or more drug, then obtains all medicines that the first candidate therapeutic scheme includes
The incompatibility data of product.The compatibility of second judgment module, all drugs for including according to the first candidate therapeutic scheme is prohibited
Avoiding data judges the first candidate therapeutic scheme with the presence or absence of incompatibility situation.First excludes module, if candidate for first
There are incompatibility situations for therapeutic scheme, then exclude the first candidate therapeutic scheme.
Optionally, the second screening subelement includes: the second acquisition module, determining module, third judgment module, the second exclusion
Module.Second obtains module, all drugs for including from first clinical application data acquisition the first candidate therapeutic scheme
Medication avoid data, the first candidate therapeutic scheme be multiple candidate therapeutic schemes in any one candidate therapeutic scheme.Really
Cover half block, for avoiding the applicable group for all drugs that data determine that the first candidate therapeutic scheme includes according to medication.Third
Judgment module, for judging whether target patient belongs to the applicable group for each drug that the first candidate therapeutic scheme includes.
Second excludes module, if being not belonging to any one or more drug that the first candidate therapeutic scheme includes for target patient
It is applicable in group, then excludes the first candidate therapeutic scheme.
Optionally, device further include: third acquiring unit, the second screening unit.Third acquiring unit, in the first sieve
Before menu member 40 screens multiple candidate therapeutic schemes according to the first clinical application data, the drug of target patient is obtained
Allergy history.Second screening unit, for being sieved according to the drug allergy history of target patient to multiple candidate therapeutic schemes
Choosing.
The embodiment of the invention provides a kind of storage medium, storage medium includes the program of storage, wherein is run in program
When equipment where control storage medium execute following steps: obtain the illness information of target patient, illness information includes at least mesh
Mark the symptom of patient；Therapeutic scheme is searched from target database according to the illness information of target patient, is obtained multiple candidates and is controlled
Treatment scheme stores the illness information and therapeutic scheme of multiple patients, the associated patient of candidate therapeutic scheme in target database
Symptom and target patient symptom between similarity meet preset condition, candidate therapeutic scheme include at least nomenclature of drug and
Drug dosage；The first clinical application data are obtained, the first clinical application data include at least the clinical application data of target medicine,
Target medicine is the drug that candidate therapeutic scheme includes；Multiple candidate therapeutic schemes are sieved according to the first clinical application data
Choosing, obtains at least one goal treatment scheme；Export goal treatment scheme.
Optionally, when program is run, equipment where control storage medium also executes following steps: according to incompatible number
It is screened according to multiple candidate therapeutic schemes；And/or data is avoided according to medication, multiple candidate therapeutic schemes are sieved
Choosing.
Optionally, when program is run, equipment where control storage medium also executes following steps: judging that the first candidate controls
Whether treatment scheme includes two or more drug, and the first candidate therapeutic scheme is any in multiple candidate therapeutic schemes
One candidate therapeutic scheme；If the first candidate therapeutic scheme includes two or more drug, it is candidate to obtain first
The incompatibility data for all drugs that therapeutic scheme includes；According to the compatibility for all drugs that the first candidate therapeutic scheme includes
Taboo data judge the first candidate therapeutic scheme with the presence or absence of incompatibility situation；If there are compatibilities for the first candidate therapeutic scheme
Situation is avoided, then excludes the first candidate therapeutic scheme.
Optionally, when program is run, equipment where control storage medium also executes following steps: from the first clinical application
Data are avoided in the medication for all drugs for including in data acquisition the first candidate therapeutic scheme, and the first candidate therapeutic scheme is multiple
Any one candidate therapeutic scheme in candidate therapeutic scheme；Data, which are avoided, according to medication determines that the first candidate therapeutic scheme includes
All drugs applicable group；Judge whether target patient belongs to the suitable of each drug that the first candidate therapeutic scheme includes
Use group；If target patient is not belonging to the applicable group for any one or more drug that the first candidate therapeutic scheme includes,
Then exclude the first candidate therapeutic scheme.
Optionally, when program is run, equipment where control storage medium also executes following steps: according to the first clinic
Before administration data screens multiple candidate therapeutic schemes, the drug allergy history of target patient is obtained；Suffered from according to target
The drug allergy history of person screens multiple candidate therapeutic schemes.
The embodiment of the invention provides a kind of computer equipments, including memory and processor, and memory is for storing packet
The information of program instruction is included, processor is used to control the execution of program instruction, real when program instruction is loaded and executed by processor
Existing following steps: obtaining the illness information of target patient, and illness information includes at least the symptom of target patient；According to target patient
Illness information therapeutic scheme is searched from target database, obtain multiple candidate therapeutic schemes, stored in target database
The illness information and therapeutic scheme of multiple patients, between the symptom of the associated patient of candidate therapeutic scheme and the symptom of target patient
Similarity meet preset condition, candidate therapeutic scheme includes at least nomenclature of drug and drug dosage；Obtain the first clinical application
Data, the first clinical application data include at least the clinical application data of target medicine, and target medicine is candidate therapeutic scheme packet
The drug included；Multiple candidate therapeutic schemes are screened according to the first clinical application data, obtain at least one goal treatment
Scheme；Export goal treatment scheme.
Optionally, it also performs the steps of when program instruction is loaded and executed by processor according to incompatibility data pair
Multiple candidate therapeutic schemes are screened；And/or data is avoided according to medication, multiple candidate therapeutic schemes are screened.
Optionally, it is also performed the steps of when program instruction is loaded and executed by processor and judges the first candidate therapeutic side
Whether case includes two or more drug, and the first candidate therapeutic scheme is any one in multiple candidate therapeutic schemes
Candidate therapeutic scheme；If the first candidate therapeutic scheme includes two or more drug, the first candidate therapeutic is obtained
The incompatibility data for all drugs that scheme includes；According to the incompatibility for all drugs that the first candidate therapeutic scheme includes
Data judge the first candidate therapeutic scheme with the presence or absence of incompatibility situation；If there are incompatibility for the first candidate therapeutic scheme
Situation then excludes the first candidate therapeutic scheme.
Optionally, it is also performed the steps of when program instruction is loaded and executed by processor from the first clinical application data
The medication taboo data for all drugs for including in the first candidate therapeutic scheme are obtained, the first candidate therapeutic scheme is multiple candidates
Any one candidate therapeutic scheme in therapeutic scheme；The institute that the first candidate therapeutic scheme includes is determined according to medication taboo data
There is the applicable group of drug；Judge whether target patient belongs to the applicable group for each drug that the first candidate therapeutic scheme includes
Body；If target patient is not belonging to the applicable group for any one or more drug that the first candidate therapeutic scheme includes, arrange
Except the first candidate therapeutic scheme.
Optionally, it also performs the steps of when program instruction is loaded and executed by processor according to the first clinical application
Before data screen multiple candidate therapeutic schemes, the drug allergy history of target patient is obtained；According to target patient
Drug allergy history screens multiple candidate therapeutic schemes.
Fig. 3 is a kind of schematic diagram of computer equipment provided in an embodiment of the present invention.As shown in figure 3, the meter of the embodiment
Machine equipment 50 is calculated to include: processor 51, memory 52 and be stored in the meter that can be run in memory 52 and on processor 51
Calculation machine program 53 realizes the therapeutic scheme recommended method in embodiment, to keep away when the computer program 53 is executed by processor 51
Exempt to repeat, not repeat one by one herein.Alternatively, realizing that therapeutic scheme pushes away in embodiment when the computer program is executed by processor 51
The function of recommending each model/unit in device does not repeat one by one herein to avoid repeating.
Computer equipment 50 can be desktop PC, notebook, palm PC and cloud server etc. and calculate equipment.
Computer equipment may include, but be not limited only to, processor 51, memory 52.It will be understood by those skilled in the art that Fig. 3 is only
It is the example of computer equipment 50, does not constitute the restriction to computer equipment 50, may include more more or fewer than illustrating
Component perhaps combines certain components or different components, such as computer equipment can also include input-output equipment, net
Network access device, bus etc..
Alleged processor 51 can be central processing unit (Central Processing Unit, CPU), can also be
Other general processors, digital signal processor (Digital Signal Processor, DSP), specific integrated circuit
(Application Specific Integrated Circuit, ASIC), field programmable gate array (Field-
Programmable Gate Array, FPGA) either other programmable logic device, discrete gate or transistor logic,
Discrete hardware components etc..General processor can be microprocessor or the processor is also possible to any conventional processor
Deng.
Memory 52 can be the internal storage unit of computer equipment 50, such as the hard disk or interior of computer equipment 50
It deposits.Memory 52 is also possible to the plug-in type being equipped on the External memory equipment of computer equipment 50, such as computer equipment 50
Hard disk, intelligent memory card (Smart Media Card, SMC), secure digital (Secure Digital, SD) card, flash card
(Flash Card) etc..Further, memory 52 can also both including computer equipment 50 internal storage unit and also including
External memory equipment.Memory 52 is for storing other programs and data needed for computer program and computer equipment.It deposits
Reservoir 52 can be also used for temporarily storing the data that has exported or will export.
It is apparent to those skilled in the art that for convenience and simplicity of description, the system of foregoing description,
The specific work process of device and unit, can refer to corresponding processes in the foregoing method embodiment, and details are not described herein.
In several embodiments provided by the present invention, it should be understood that disclosed system, device and method can be with
It realizes by another way.For example, the apparatus embodiments described above are merely exemplary, for example, the unit
It divides, only a kind of logical function partition, there may be another division manner in actual implementation, for example, multiple units or group
Part can be combined or can be integrated into another system, or some features can be ignored or not executed.Another point, it is shown
Or the mutual coupling, direct-coupling or communication connection discussed can be through some interfaces, device or unit it is indirect
Coupling or communication connection can be electrical property, mechanical or other forms.
The unit as illustrated by the separation member may or may not be physically separated, aobvious as unit
The component shown may or may not be physical unit, it can and it is in one place, or may be distributed over multiple
In network unit.It can select some or all of unit therein according to the actual needs to realize the mesh of this embodiment scheme
's.
It, can also be in addition, the functional units in various embodiments of the present invention may be integrated into one processing unit
It is that each unit physically exists alone, can also be integrated in one unit with two or more units.Above-mentioned integrated list
Member both can take the form of hardware realization, can also realize in the form of hardware adds SFU software functional unit.
The above-mentioned integrated unit being realized in the form of SFU software functional unit can store and computer-readable deposit at one
In storage media.Above-mentioned SFU software functional unit is stored in a storage medium, including some instructions are used so that a computer
It is each that device (can be personal computer, server or network equipment etc.) or processor (Processor) execute the present invention
The part steps of embodiment the method.And storage medium above-mentioned includes: USB flash disk, mobile hard disk, read-only memory (Read-
Only Memory, ROM), random access memory (Random Access Memory, RAM), magnetic or disk etc. it is various
It can store the medium of program code.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Within mind and principle, any modification, equivalent substitution, improvement and etc. done be should be included within the scope of the present invention.
Claims (10)
1. a kind of therapeutic scheme recommended method, which is characterized in that the described method includes:
The illness information of target patient is obtained, the illness information includes at least the symptom of the target patient；
Therapeutic scheme is searched from target database according to the illness information of the target patient, obtains multiple candidate therapeutic sides
Case, the illness information and therapeutic scheme of multiple patients are stored in the target database, and the candidate therapeutic scheme is associated
Similarity between the symptom of patient and the symptom of the target patient meets preset condition, and the candidate therapeutic scheme is at least wrapped
Include nomenclature of drug and drug dosage；
The first clinical application data are obtained, the first clinical application data include at least the clinical application data of target medicine,
The target medicine is the drug that the candidate therapeutic scheme includes；
The multiple candidate therapeutic scheme is screened according to the first clinical application data, at least one target is obtained and controls
Treatment scheme；
Export the goal treatment scheme.
2. the method according to claim 1, wherein the first clinical application data include incompatible number evidence
Data are avoided with medication, described to screen according to the first clinical application data to the multiple candidate therapeutic scheme, packet
It includes:
The multiple candidate therapeutic scheme is screened according to the incompatibility data；
And/or
Data are avoided according to the medication to screen the multiple candidate therapeutic scheme.
3. according to the method described in claim 2, it is characterized in that, it is described according to the incompatibility data to the multiple time
Therapeutic scheme is selected to be screened, comprising:
Judge whether the first candidate therapeutic scheme includes two or more drug, and the first candidate therapeutic scheme is institute
State any one candidate therapeutic scheme in multiple candidate therapeutic schemes；
If the first candidate therapeutic scheme includes two or more drug, the first candidate therapeutic side is obtained
The incompatibility data for all drugs that case includes；
The incompatible number for all drugs for including according to the first candidate therapeutic scheme is it is judged that first candidate therapeutic
Scheme whether there is incompatibility situation；
If there are incompatibility situations for the first candidate therapeutic scheme, the first candidate therapeutic scheme is excluded.
4. according to the method described in claim 2, it is characterized in that, described avoid data to the multiple time according to the medication
Therapeutic scheme is selected to be screened, comprising:
Data are avoided in the medication for all drugs for including from the first clinical application data acquisition the first candidate therapeutic scheme,
The first candidate therapeutic scheme is any one candidate therapeutic scheme in the multiple candidate therapeutic scheme；
The applicable group for all drugs that data determine that the first candidate therapeutic scheme includes is avoided according to the medication；
Judge whether the target patient belongs to the applicable group for each drug that the first candidate therapeutic scheme includes；
If the target patient is not belonging to being applicable in for any one or more drug that the first candidate therapeutic scheme includes
Group then excludes the first candidate therapeutic scheme.
5. method according to any one of claims 1 to 4, which is characterized in that described according to first clinical application
Before data screen the multiple candidate therapeutic scheme, the method also includes:
Obtain the drug allergy history of the target patient；
The multiple candidate therapeutic scheme is screened according to the drug allergy history of the target patient.
6. a kind of therapeutic scheme recommendation apparatus, which is characterized in that described device includes:
First acquisition unit, for obtaining the illness information of target patient, the illness information includes at least the target patient
Symptom；
Searching unit obtains more for searching therapeutic scheme from target database according to the illness information of the target patient
A candidate therapeutic scheme, the illness information and therapeutic scheme of multiple patients are stored in the target database, and the candidate controls
Similarity between the symptom of the associated patient for the treatment of scheme and the symptom of the target patient meets preset condition, and the candidate controls
Treatment scheme includes at least nomenclature of drug and drug dosage；
Second acquisition unit, for obtaining the first clinical application data, the first clinical application data include at least target medicine
The clinical application data of product, the target medicine are the drug that the candidate therapeutic scheme includes；
First screening unit, for being screened according to the first clinical application data to the multiple candidate therapeutic scheme,
Obtain at least one goal treatment scheme；
Output unit, for exporting the goal treatment scheme.
7. device according to claim 6, which is characterized in that the first clinical application data include incompatible number evidence
Data are avoided with medication, first screening unit includes:
First screening subelement, for being screened according to the incompatibility data to the multiple candidate therapeutic scheme；
And/or
Second screening subelement, screens the multiple candidate therapeutic scheme for avoiding data according to the medication.
8. device according to claim 7, which is characterized in that described first, which screens subelement, includes:
First judgment module, for judging whether the first candidate therapeutic scheme includes two or more drug, described
One candidate therapeutic scheme is any one candidate therapeutic scheme in the multiple candidate therapeutic scheme；
First obtains module, if including two or more drug for the first candidate therapeutic scheme, obtains
The incompatibility data for all drugs that the first candidate therapeutic scheme includes；
Second judgment module, the incompatible numbers of all drugs for including according to the first candidate therapeutic scheme it is judged that
The first candidate therapeutic scheme whether there is incompatibility situation；
First exclusion module excludes described first if there are incompatibility situations for the first candidate therapeutic scheme
Candidate therapeutic scheme.
9. a kind of storage medium, which is characterized in that the storage medium includes the program of storage, wherein run in described program
When control the storage medium where equipment perform claim require any one of 1 to 5 described in therapeutic scheme recommended method.
10. a kind of computer equipment, including memory and processor, the memory is for storing the letter including program instruction
Breath, the processor are used to control the execution of program instruction, it is characterised in that: described program instruction is loaded and executed by processor
The step of therapeutic scheme recommended method described in Shi Shixian claim 1 to 5 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811606759.9A CN109859851A (en) | 2018-12-27 | 2018-12-27 | A kind of therapeutic scheme recommended method and device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811606759.9A CN109859851A (en) | 2018-12-27 | 2018-12-27 | A kind of therapeutic scheme recommended method and device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109859851A true CN109859851A (en) | 2019-06-07 |
Family
ID=66892671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811606759.9A Pending CN109859851A (en) | 2018-12-27 | 2018-12-27 | A kind of therapeutic scheme recommended method and device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109859851A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110444288A (en) * | 2019-07-24 | 2019-11-12 | 卓尔智联(武汉)研究院有限公司 | Auxiliary diagnostic equipment, method and readable storage medium storing program for executing based on complex network |
| CN110491470A (en) * | 2019-08-14 | 2019-11-22 | 一点圣手网络科技有限公司 | A kind of method and device for recommending coordinating program |
| CN110504036A (en) * | 2019-08-27 | 2019-11-26 | 北京明日汇科技管理有限公司 | Patient care method and system based on big data cloud platform |
| CN110689939A (en) * | 2019-08-27 | 2020-01-14 | 天津开心生活科技有限公司 | Recommendation method and device for medication sequence, readable medium and electronic equipment |
| CN110942814A (en) * | 2019-11-28 | 2020-03-31 | 上海正雅齿科科技股份有限公司 | Statistical method and statistical system for wearing information of shell-shaped tooth appliance |
| CN111768867A (en) * | 2020-07-01 | 2020-10-13 | 北京爱康宜诚医疗器材有限公司 | Treatment scheme determination method and device |
| CN111785366A (en) * | 2020-06-29 | 2020-10-16 | 平安科技（深圳）有限公司 | Method and device for determining patient treatment scheme and computer equipment |
| CN112309579A (en) * | 2020-11-26 | 2021-02-02 | 微医云(杭州)控股有限公司 | Method and device for recommending treatment scheme, electronic equipment and storage medium |
| CN112331356A (en) * | 2020-11-26 | 2021-02-05 | 微医云(杭州)控股有限公司 | Method and device for recommending treatment scheme, electronic equipment and storage medium |
| CN112837795A (en) * | 2021-01-25 | 2021-05-25 | 南通市第一人民医院 | Acute poisoning treatment information resource library sharing system and method |
| CN113096795A (en) * | 2019-12-23 | 2021-07-09 | 四川医枢科技股份有限公司 | Multi-source data-aided clinical decision support system and method |
| CN113409911A (en) * | 2021-07-14 | 2021-09-17 | 浙江大学 | Traditional Chinese medicine formula recommendation method and system based on case clinical phenotype association degree |
| CN115910323A (en) * | 2022-11-16 | 2023-04-04 | 山东仲雅信息技术有限公司 | Treatment scheme selection method, device, equipment and storage medium |
| CN116013454A (en) * | 2022-12-30 | 2023-04-25 | 安徽医科大学第一附属医院 | Negative pressure wound treatment device and target negative pressure treatment parameter planning method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102737165A (en) * | 2012-06-07 | 2012-10-17 | 北京太元通软件科技有限公司 | Clinical medication decision support system |
| CN106503465A (en) * | 2016-10-27 | 2017-03-15 | 李露青 | Information push-delivery apparatus |
| CN106529148A (en) * | 2016-10-27 | 2017-03-22 | 李露青 | Information pushing apparatus |
| CN108986879A (en) * | 2018-05-31 | 2018-12-11 | 平安医疗科技有限公司 | Drug recommended method, device, computer equipment and storage medium |
-
2018
- 2018-12-27 CN CN201811606759.9A patent/CN109859851A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102737165A (en) * | 2012-06-07 | 2012-10-17 | 北京太元通软件科技有限公司 | Clinical medication decision support system |
| CN106503465A (en) * | 2016-10-27 | 2017-03-15 | 李露青 | Information push-delivery apparatus |
| CN106529148A (en) * | 2016-10-27 | 2017-03-22 | 李露青 | Information pushing apparatus |
| CN108986879A (en) * | 2018-05-31 | 2018-12-11 | 平安医疗科技有限公司 | Drug recommended method, device, computer equipment and storage medium |
Non-Patent Citations (1)
| Title |
|---|
| 爱尔眼科医院集团医疗管理中心编著: "眼科临床用药手册", 31 March 2012, 北京：人民军医出版社, pages: 128 - 130 * |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110444288A (en) * | 2019-07-24 | 2019-11-12 | 卓尔智联(武汉)研究院有限公司 | Auxiliary diagnostic equipment, method and readable storage medium storing program for executing based on complex network |
| CN110491470A (en) * | 2019-08-14 | 2019-11-22 | 一点圣手网络科技有限公司 | A kind of method and device for recommending coordinating program |
| CN110504036A (en) * | 2019-08-27 | 2019-11-26 | 北京明日汇科技管理有限公司 | Patient care method and system based on big data cloud platform |
| CN110689939A (en) * | 2019-08-27 | 2020-01-14 | 天津开心生活科技有限公司 | Recommendation method and device for medication sequence, readable medium and electronic equipment |
| CN110942814A (en) * | 2019-11-28 | 2020-03-31 | 上海正雅齿科科技股份有限公司 | Statistical method and statistical system for wearing information of shell-shaped tooth appliance |
| CN110942814B (en) * | 2019-11-28 | 2023-10-27 | 正雅齿科科技(上海)有限公司 | Statistical method and statistical system for wearing information of shell-shaped dental appliance |
| CN113096795A (en) * | 2019-12-23 | 2021-07-09 | 四川医枢科技股份有限公司 | Multi-source data-aided clinical decision support system and method |
| CN113096795B (en) * | 2019-12-23 | 2023-10-03 | 四川医枢科技有限责任公司 | Multi-source data-aided clinical decision support system and method |
| CN111785366A (en) * | 2020-06-29 | 2020-10-16 | 平安科技（深圳）有限公司 | Method and device for determining patient treatment scheme and computer equipment |
| WO2021151295A1 (en) * | 2020-06-29 | 2021-08-05 | 平安科技（深圳）有限公司 | Method, apparatus, computer device, and medium for determining patient treatment plan |
| CN111768867A (en) * | 2020-07-01 | 2020-10-13 | 北京爱康宜诚医疗器材有限公司 | Treatment scheme determination method and device |
| CN111768867B (en) * | 2020-07-01 | 2024-02-27 | 北京爱康宜诚医疗器材有限公司 | Treatment scheme determination method and device |
| CN112331356A (en) * | 2020-11-26 | 2021-02-05 | 微医云(杭州)控股有限公司 | Method and device for recommending treatment scheme, electronic equipment and storage medium |
| CN112309579A (en) * | 2020-11-26 | 2021-02-02 | 微医云(杭州)控股有限公司 | Method and device for recommending treatment scheme, electronic equipment and storage medium |
| CN112837795A (en) * | 2021-01-25 | 2021-05-25 | 南通市第一人民医院 | Acute poisoning treatment information resource library sharing system and method |
| CN113409911A (en) * | 2021-07-14 | 2021-09-17 | 浙江大学 | Traditional Chinese medicine formula recommendation method and system based on case clinical phenotype association degree |
| CN115910323A (en) * | 2022-11-16 | 2023-04-04 | 山东仲雅信息技术有限公司 | Treatment scheme selection method, device, equipment and storage medium |
| CN115910323B (en) * | 2022-11-16 | 2023-09-29 | 山东仲雅信息技术有限公司 | Treatment scheme selection method, device, equipment and storage medium |
| CN116013454A (en) * | 2022-12-30 | 2023-04-25 | 安徽医科大学第一附属医院 | Negative pressure wound treatment device and target negative pressure treatment parameter planning method |
| CN116013454B (en) * | 2022-12-30 | 2023-09-22 | 安徽医科大学第一附属医院 | Negative pressure wound treatment device and target negative pressure treatment parameter planning method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109859851A (en) | A kind of therapeutic scheme recommended method and device | |
| US11301809B2 (en) | Care plan administration | |
| Zeng et al. | Continuous renal replacement therapy (CRRT) for rhabdomyolysis | |
| CN108648792A (en) | Medication information management system, method and terminal device | |
| Ciccone et al. | Continuous versus intermittent physiological monitoring for acute stroke | |
| CN108777163A (en) | Based on the comprehensive reasonable benefit/risk infusion pre-warning monitoring method of doctor, nursing, pharmacy | |
| CN109273098A (en) | A kind of pharmaceutical effectiveness prediction technique and device based on intelligent decision | |
| CN109712712A (en) | A kind of health evaluating method, health evaluating device and computer readable storage medium | |
| Deepika et al. | Iot based elderly monitoring system | |
| CN106650232A (en) | Method for calculating probability of occurrence of disease according to drugs and system thereof | |
| CN106709225A (en) | Early-warning method, device and system for diabetic retinopathy | |
| Antonelli et al. | MeTA: Characterization of medical treatments at different abstraction levels | |
| Novell et al. | Laparoscopic management of Spigelian hernia. | |
| Nadda et al. | Weighted extreme learning machine for dengue detection with class-imbalance classification | |
| EP4044192A1 (en) | Method, program, device, and system for assisting determination of at least one of dosage form and dosage of drug | |
| WO2020181484A1 (en) | Patient monitoring method and device, and computer-readable storage medium | |
| Souvignet et al. | Evaluation of automated term groupings for detecting anaphylactic shock signals for drugs | |
| Lim et al. | The use of machine learning for investigating the role of plastic surgeons in anatomical injuries: A retrospective observational study | |
| Li et al. | Remarkably Widened QRS Complex Following a Lethal Dose of Propafenone—An Ominous Sign | |
| Hancock et al. | Metastability as a neuromechanistic biomarker of schizophrenia pathology | |
| Khaja | Signal fusion and semantic similarity evaluation for social media based adverse drug event detection | |
| Vo et al. | Towards VNUMED for healthcare research activities in Vietnam | |
| JP2004240734A (en) | Disease state estimating system | |
| CN113160913B (en) | Rescue medication management method, system and storage medium for medical rescue vehicle | |
| CN115171897A (en) | Early warning system for drug cardiotoxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |